Home LiteratureArticle Details
PMID: 9589230 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study.

Diabetes care ·Vol. 21 ·No. 5 ·1998-05-00 ·Pages 717-24

Luo J, Rizkalla SW, Vidal H, Oppert JM, Colas C, Boussairi A, Guerre-Millo M, Chapuis AS, Chevalier A, Durand G, Slama G

Abstract

To evaluate the effect of a moderate dose of fish oil on glycemic control and in vivo insulin action in type 2 diabetic men with elevated plasma triacylglycerols and to determine the effect of the same treatment on gene expression of GLUT4, lipoprotein lipase (LPL), and hormone-sensitive lipase (HSL) in the abdominal adipose tissue. A total of 12 type 2 diabetic men were randomly allocated to 2 months of 6 g daily of either fish oil or sunflower oil, separated by a 2-month washout interval, in a double-blind crossover design. For glucose metabolism, 2 months of fish oil supplementation compared with sunflower oil led to similar fasting plasma insulin, glucose, and HbA1c. Basal hepatic glucose production did not increase after fish oil. There was no difference in insulin suppression of hepatic glucose production nor in insulin stimulation of whole-body glucose disposal measured by the euglycemic-hyperinsulinemic clamp. Fish oil did not ameliorate the low mRNA level of GLUT4 in adipose tissue of these patients. For lipid profile, fish oil lowered plasma triacylglycerol more than sunflower oil (P < 0.05) and tended to increase the amount of mRNA of both LPL and HSL in adipose tissue. A moderate dose of fish oil did not lead to deleterious effects on glycemic control or whole-body insulin sensitivity in type 2 diabetic men, with preserved triacylglycerol-lowering capacities.

MeSH Terms
Basal Metabolism/drug effects Blood Glucose/drug effects,metabolism Body Weight/drug effects Cross-Over Studies Diabetes Mellitus, Type 2/blood,drug therapy Diet Dietary Fats, Unsaturated/administration & dosage,therapeutic use Double-Blind Method Energy Intake/drug effects Erythrocyte Membrane/chemistry,drug effects Fatty Acids, Omega-3/administration & dosage,therapeutic use Gene Expression/drug effects,genetics Glucose/metabolism Glucose Transporter Type 4 Humans Insulin/blood Lipase/drug effects,genetics Lipids/blood Lipoproteins/blood,drug effects Male Middle Aged Monosaccharide Transport Proteins/drug effects,genetics Muscle Proteins Phospholipids/blood,chemistry RNA, Messenger/analysis Time Factors Treatment Outcome
Chemicals
Blood Glucose Dietary Fats, Unsaturated Fatty Acids, Omega-3 Glucose Transporter Type 4 Insulin Lipids Lipoproteins Monosaccharide Transport Proteins Muscle Proteins Phospholipids RNA, Messenger SLC2A4 protein, human Lipase Glucose
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Luo J
Department of Diabetes, INSERM U341, Hôtel-Dieu, Paris, France.
Rizkalla S W
Vidal H
Oppert J M
Colas C
Boussairi A
Guerre-Millo M
Chapuis A S
Chevalier A
Durand G
Slama G
Article Info
Journal
Diabetes care
Abbr.
Diabetes Care
ISSN
0149-5992
Published
1998-05-00
Pages
717-24
Language
English
Region
United States
NLM ID
7805975
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com